Table 2.
Management and outcomes
| No (%) | |
| CTCAE grade | |
| 2 | 11 (42.3) |
| 3 | 13 (50.0) |
| 4 | 2 (7.7) |
| Refractory/resistant | |
| Steroid refractory | 12 (46.2) |
| Steroid resistant | 14 (53.8) |
| Maximum steroid dose, prednisone equivalent | |
| Range (median) | 30–1250 mg (100 mg) |
| ≥60 mg* | 21 (80.7) |
| Additional Immune modulator | |
| TNF antagonist | 21 (80.8) |
| Mycophenolate mofetil | 9 (34.6) |
| Cyclophosphamide | 1 (3.8) |
| >1 | 5 (19.2) |
| Response to additional immune modulator | |
| Durable improvement | 10 (38.5) |
| Transient improvement | 13 (50.0) |
| No improvement | 3 (11.5) |
| Outcomes | |
| Mortality due to pneumonitis | 6 (23.1) |
| Mortality due to infection | 3 (11.5) |
*All patients with steroid refractory pneumonitis were treated with ≥60 mg.
CTCAE, common terminology criteria for adverse events; TNF, tumor necrosis factor.